98%
921
2 minutes
20
Heterotopic ossifications (HOs) are the pathologic process by which bone inappropriately forms outside of the skeletal system. Despite HOs being a persistent clinical problem in the general population, there are no definitive strategies for their prevention and treatment due to a limited understanding of the cellular and molecular mechanisms contributing to lesion development. One disease in which the development of heterotopic subcutaneous ossifications (SCOs) leads to morbidity is Albright hereditary osteodystrophy (AHO). Albright hereditary osteodystrophy is caused by heterozygous inactivation of , the gene that encodes the α-stimulatory subunit (Gα) of G proteins. Previously, we had shown using our laboratory's AHO mouse model that SCOs develop around hair follicles. Here we show that SCO formation occurs due to inappropriate expansion and osteogenic differentiation of cells that express alpha-smooth muscle actin and that are located within the dermal sheath. We also show in AHO patients and mice that ( expression is upregulated in regions of SCO formation and that elimination of in male AHO mice leads to earlier development, greater severity, and acceleration of formation of SCOs. These studies provide key insights into the cellular and molecular mechanisms contributing to SCO development and have implications for potential therapeutic modalities not only for AHO patients but also for patients suffering from HOs with other etiologies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009542 | PMC |
http://dx.doi.org/10.1093/jbmrpl/ziaf038 | DOI Listing |
Front Genet
August 2025
Department of Endocrinology and Metabolism, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.
Objective: Pseudohypoparathyroidism type 1B (PHP1B), caused by abnormal methylation of the gene leading to parathyroid hormone (PTH) resistance, lacks Albright hereditary osteodystrophy features and is often misdiagnosed. PHP1B and Gitelman syndrome (GS) share overlapping features, including hypokalemia, hypocalcemia, hypomagnesemia, and metabolic alkalosis, posing challenges in clinical differentiation. This study aimed to explore the clinical characteristics, diagnostic strategies, and therapeutic responses of PHP1B presenting with hypokalemia and to explicitly address the diagnostic challenge of differentiating it from GS.
View Article and Find Full Text PDFAnn Med Surg (Lond)
July 2025
Department of Internal Medicine, Tribhuvan University, Institute of Medicine, Maharajgunj, Kathmandu, Nepal.
Introduction: Pseudohypoparathyroidism (PHP), a rare genetic disorder is characterized by features of hypoparathyroidism due to tissue resistance to effect of parathyroid hormone (PTH).
Case Presentation: A 1-year-old girl, the first child of healthy non-consanguineous parents with no family history of similar conditions or skeletal deformities, presented with small bumps on her leg, wrist, and periumbilical region for 6 months. Lab results revealed high serum phosphate, low vitamin D, normal calcium, and elevated PTH levels.
Eur J Endocrinol
May 2025
Department of Endocrinology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China.
Objective: We assessed pediatric patients with clinically diagnosed pseudohypoparathyroidism (PHP), pseudopseudohypoparathyroidism (PPHP), and progressive osseous heteroplasia (POH) for genetic and epigenetic defects in GNAS and characterized their clinical features.
Design: We enrolled a total of 87 patients in our study, 70 patients underwent genetic analysis. We compared the clinical manifestations according to the previously reported inactivating PTH/PTHrP signaling disorder (iPPSD) classification combined with conventional clinical classification.
Front Endocrinol (Lausanne)
May 2025
Department of Endocrinology and Metabolic Diseases, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
Introduction: Pseudohypoparathyroidism (PHP) is a rare genetically determined disease with a wide range of symptoms related to target organs' resistance to parathyroid hormone (PTH). Lack or insufficient action of PTH on effector organs causes hypocalcemia and hyperphosphatemia. Some patients may have characteristic features of Albright hereditary osteodystrophy (AHO).
View Article and Find Full Text PDFJBMR Plus
May 2025
Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT 06030, United States.
Heterotopic ossifications (HOs) are the pathologic process by which bone inappropriately forms outside of the skeletal system. Despite HOs being a persistent clinical problem in the general population, there are no definitive strategies for their prevention and treatment due to a limited understanding of the cellular and molecular mechanisms contributing to lesion development. One disease in which the development of heterotopic subcutaneous ossifications (SCOs) leads to morbidity is Albright hereditary osteodystrophy (AHO).
View Article and Find Full Text PDF